Latest information on COVID-19
Support teaching, research, and patient care.
I am an instructor in pediatric hematology/oncology. I completed fellowship in pediatric hematology/oncology at Stanford and previously trained in internal medicine and pediatrics (med-peds) at CHOP and Penn. I am passionate about the intersection between clinical care and clinical research, and committed to understanding the long-term effects of childhood cancer therapies over the course of our patients' lifetimes. It is through this type of research that we can learn how to modify our initial treatments to ensure the best possible outcomes in the long run. Additionally, I aim to develop community-based partnerships to translate evidence-based survivorship research to real-world clinical practice settings in communities with socioeconomic disadvantages and structural barriers to long-term follow-up care by targeting social determinants of health with the goal of improving access to care and health equity for adolescent/young adult (AYA) cancer survivors.
I am involved with clinical research related to cancer survivorship, with a particular focus on late effects of childhood cancer treatments and community partnerships to improve health equity for adolescent/young adult cancer survivors in under-resourced settings.Areas of focus include:Late effects of novel therapies:This research relates to the use of BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL), as little is known about the long-term and late effects of these therapies in young people. I lead the New Agents task force for the Children's Oncology Group Long-Term Follow-Up Guidelines.Community partnerships to improve health equity for AYA cancer survivors:This is a new area of research for me that involves developing community partnerships to translate evidence-based survivorship research to real-world clinical practice settings in communities with socioeconomic disadvantages and structural barriers to long-term follow-up care. This research will target social determinants of health with the goal of improving access to care and health equity. I plan to utilize community-based participatory research methods to understand the key issues facing AYA cancer survivors and to collaboratively develop multi-level pragmatic interventions to improve health equity and access to survivorship care for AYA cancer survivors in communities with socioeconomic disadvantages.Collaboration between oncology-survivorship-primary care:In collaboration with a multidisciplinary team, I contributed to the development of an online continuing medical education cancer survivorship course for primary care physicians and other healthcare providers, which is available here: https://mededucation.stanford.edu/courses/health-after-cancer/We are now in the process of adapting this course for cancer survivors and caregivers.Adolescent/young adult cancer survivorship care:As a collaboration with the Stanford Adolescent/Young Adult Cancer (SAYAC) program, I see patients in a pilot clinic for young adult survivors of childhood leukemia and bone marrow transplant, with a focus on cancer survivorship and transitioning to adult-focused care and from active cancer treatment to long-term follow-up care.
Pharmacogenomic Analysis in Pediatric Acute Lymphoblastic Leukemia
This is a retrospective biobank study evaluating the impact of novel genetic variants in a
population of 6-mercaptopurine treated pediatric acute lymphoblastic leukemia patients.
View full details